Rifampin in initial treatment of pulmonary tuberculosis. A.U.S. Public Health Service tuberculosis therapy trial.
D000293:Adolescent; D000328:Adult; D000410:Alanine Transaminase / Q000378:metabolism; D001431:Bacteriological Techniques; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D004977:Ethambutol / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use; D007958:Leukocyte Count; D008099:Liver / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009169:Mycobacterium tuberculosis / Q000302:isolation & purification; D011859:Radiography; D012293:Rifampin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013183:Sputum / Q000382:microbiology; D013307:Streptomycin / Q000627:therapeutic use; D014397:Tuberculosis, Pulmonary / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000201:enzymology / Q000382:microbiology
D004977:Ethambutol; D000410:Alanine Transaminase; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin